CN104586837A - Application of cipadessa cinerascens A and analogues thereof in preparation for anti-depression medicines or foods - Google Patents
Application of cipadessa cinerascens A and analogues thereof in preparation for anti-depression medicines or foods Download PDFInfo
- Publication number
- CN104586837A CN104586837A CN201410826548.1A CN201410826548A CN104586837A CN 104586837 A CN104586837 A CN 104586837A CN 201410826548 A CN201410826548 A CN 201410826548A CN 104586837 A CN104586837 A CN 104586837A
- Authority
- CN
- China
- Prior art keywords
- gray wool
- mice
- depression
- cipadessa
- miq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a new application of cipadessa cinerascens A and analogues thereof, and specifically relates to an application thereof in preparation for anti-depression medicines or foods. The structure of the xylocarpus granatum sendanin H is shown in a structural formula (1). Experiments prove that the cipadessa cinerascens A and analogues thereof have an exact curative effect on depression, and the curative effect is basically equivalent to the effect of a common anti-depression medicine venlafaxine; meanwhile, because the cipadessa cinerascens A is the extraction ingredient of a natural product, the cipadessa cinerascens A is low in side effects on a human body, and capable of being used for a long time.
Description
Technical field
The present invention relates to the novelty teabag of a kind of gray wool Cipadessa baecifera Miq A and analog thereof, be specifically related to it and preparing the purposes in anti-depression drug or food.
Background technology
Depression is a kind of mental sickness seriously jeopardizing human physical and mental health, main manifestations is anhedonia, hebetude, with other psychology in various degree such as anxiety, sleep disorder and (or) somatization, Serious depression patient is often with very high suicide risk.Incomplete statistics, Chinese depression prevalence about 3%-5%, patient numbers is more than 26,000,000.At present clinically the treatment of depression mainly based on Drug therapy, the existing medicine overwhelming majority exist onset delay, remission not thoroughly, the limitation such as the high and side effect of relapse rate is large.The newly-developed antidepressant of development of new, safety becomes the current life science especially focus of the research of neuroscience field and difficult point.
Natural medicinal plants causes extensive concern gradually with its safety, hypotoxicity, few side effects, efficient, the feature such as to have no drug resistance.It is with a long history that China applies traditional natural medicinal plants, and natural pharmaceutical resources enriches, widely distributed, has and well researches and develops basis.Large quantity research shows, natural plant extracts has antiinflammatory, antitumor, defying age isoreactivity, also shows good development and application prospect at anti-depression aspect.The antidepressant activity plant component found mainly contains the type compounds such as benzo dianthrone class, flavonoid, oligosaccharides, alkaloids, phloroglucinol derivatives, sesquiterpenoids, Diterpenes, triterpenes, saponin, organic acid.Flavone compound in Herba Hyperici Monogyni by improving maincenter Monoamine, suppress synaptosome to monoamine-reuptake play antidepressant effect show as obviously shorten forced swimming test (forced swimming test FST) and outstanding tail test (tail suspension test TST) test in the mice dead time, the preparation produced by its extract is widely used in treatment in all states of America and Europe clinically, mild depression.Rhizoma Zingiberis Recens extract curcumin has been proved certain antidepressant effect, its effect may be relevant with furan system, further research finds, curcumin significantly can increase frontal cortex, Hippocampus and hypothalamic tuber on content of monoamine transmitters, and its antidepressant effect can be relevant by Erk-BDNF-CREB signal pathway.Other are as have also discovered antidepressant effective ingredient from the extract of Semen Arecae, Radix Morindae Officinalis etc.Natural medicinal ingredients is complicated, brings limitation to its extensive use clinically.The separation and purification of natural medicinal plants antidepressant effect active component, especially effective monomer component and activity identification become one of important directions of antidepressant drug research and development.
Xylocarpus granatum (lian) (Xylocarpus granatum Koenig.) belongs to Meliaceae Xylocarpus Koenig, uses traditionally as astringent, antipyretic, and can be used for the diseases such as treatment malaria, thrush, cholera, dysentery and diarrhoea.The limonoid (limonoids) be rich in xylocarpus granatum is that the large class that occurring in nature exists has the triterpenes secondary metabolite of complex three-dimensional topological structure, and the complex structure of this compounds is changeable.Large quantifier elimination finds, limonoid demonstrates the biologic activity of wide spectrum, as antibacterial, AntiHIV1 RT activity, parasite killing, malaria, anti-botullnus, antiallergic, check melanin formation, antiinflammatory, antitumor and neuroprotective etc.Multinomial research has been carried out at present about the extract of xylocarpus granatum, be used for the treatment of diabetes and dyslipidemia as patent CN200680041586.X discloses Xylocarpus Koenig extract, wherein biologically-active moiety comprises gray wool Cipadessa baecifera Miq A(cipadesin A) etc. various ingredients; Patent CN201210552780.1 discloses the activity that xylocarpus granatum element in heptan (xylogranatumin G) has obvious inhibition tumor cell; Patent CN201210564022.1 discloses xylocarpus granatum alkali A prime (granatumine A) as the application of protein tyrosine phosphatase inhibitor in treatment diabetes, obesity and complication thereof.Visible, there is no in prior art and xylocarpus granatum and/or xylocarpus granatum extract monomer component be used for the treatment of or the purposes of prevention of depression.
Summary of the invention
A kind of gray wool Cipadessa baecifera Miq A and analog thereof is the object of the present invention is to provide to prepare the purposes in anti-depression drug or food, gray wool Cipadessa baecifera Miq A has higher safety and human body adaptability as a kind of natural plant extracts, and because toxic and side effects is little, the medium-term and long-term use of food can be added into.
Technical scheme of the present invention is as follows:
A kind of gray wool Cipadessa baecifera Miq A(cipadesin A) preparing the purposes in anti-depression drug or food, the structure of described gray wool Cipadessa baecifera Miq A as shown in structural formula (1),
Structural formula (1).
Gray wool Cipadessa baecifera Miq category-A is preparing the purposes in anti-depression drug or food like thing, described gray wool Cipadessa baecifera Miq category-A like the structure of thing as shown in structural formula (2),
Structural formula (2),
Wherein R
1or R
2be selected from hydrogen, carbonyl, C
1~ C
18substituted or non-substituted alkyl, C
1~ C
18substituted or non-substituted aryl.
Depression of the present invention comprises individual event depression clinically or two-way depression.
Medicine of the present invention comprises based on the medicine of therapeutic purposes and the health product based on prevention object.
The present invention protects the purposes of gray wool Cipadessa baecifera Miq A in the medicine preparing Cure of depression or food; as long as therefore add the compositions of gray wool Cipadessa baecifera Miq A or product based on antidepressant object all belong to the scope that the present invention protects, and be not particularly limited in this product and only have gray wool Cipadessa baecifera Miq A component.And as known in the field, other effective ingredient or adjuvant can be added when being prepared as medicine or food, forming final products.The adjuvant that can add comprises excipient, pharmaceutical carrier, disintegrating agent, filler etc.
The present invention protects the purposes of derivant in the medicine preparing Cure of depression or food of gray wool Cipadessa baecifera Miq A, and described derivant is with structural formula (2) for parent nucleus, R
1or R
2be selected from hydrogen, carbonyl, C
1~ C
18substituted or non-substituted alkyl, C
1~ C
18substituted or non-substituted aryl.
The invention provides the novelty teabag of a kind of gray wool Cipadessa baecifera Miq A, it can be applicable to prepare the medicine of depression, health product or food.When being prepared as medicine, the effective dose of gray wool Cipadessa baecifera Miq A is oral 0.5-5mg/kg, (or injection 0.1-2mg/Kg); When being prepared as health product, the effective dose of gray wool Cipadessa baecifera Miq A is oral 0.1-1mg/kg; When being prepared as food, the gray wool Cipadessa baecifera Miq A adding 0.1-1mg/kg can be selected in beverage or food.
Beneficial effect of the present invention is:
The invention provides the novelty teabag of a kind of gray wool Cipadessa baecifera Miq A, it can be applicable to prepare the medicine of depression, health product or food.Experiment proves, gray wool Cipadessa baecifera Miq A and analog thereof have definite curative effect to depression, and have certain angst resistance effect, basic suitable with the effect of antidepressant common medicine venlafaxine; Meanwhile, because it is natural product extraction composition, little to the side effect of human body, can life-time service.
Accompanying drawing explanation
Fig. 1 is the flow chart of embodiment test method;
Fig. 2 is the experimental result of the mouse forced swimming test of embodiment 2;
Fig. 3 is the experimental result of the Tail suspension test of embodiment 3;
Fig. 4 is the experimental result of the mice spacious field experiment of embodiment 4;
Fig. 5 is the experimental result of the spontaneous activity in mice experiment of embodiment 5.
Detailed description of the invention
The preparation of embodiment 1 gray wool Cipadessa baecifera Miq A
Gray wool Cipadessa baecifera Miq A is separation and Extraction monomer out from xylocarpus granatum, reaches more than 98% through Purity.
The extraction separation and purification method of gray wool Cipadessa baecifera Miq A
Get xylocarpus granatum medical material (fruits and seeds) about 20 Kg after pulverizing, extract with 95% ethanol merceration, each soak time is one week, extracts 3 times.Extracting liquid filtering, is evaporated to paste, obtains extractum.Extractum is suspended in water, uses petroleum ether, dichloromethane and extraction into ethyl acetate respectively, extract concentrating under reduced pressure, obtain petroleum ether part extractum, dichloromethane fractions extractum and ethyl acetate portion extractum.Adopt silica gel column chromatography, polydextran gel, Preparative TLC method to be separated with the chemical composition of preparative high performance liquid chromatography to above extractum, the gray wool Cipadessa baecifera Miq A monomeric compound obtained is white powdery solids.Employing HR-ESI-MS,
1h NMR,
13c NMR, HMBC and NOESY authenticating compound structure.
Gray wool Cipadessa baecifera Miq A is accredited as white powdery solids.ESI-MS ([M+H]
+m/z 571), determine that molecular formula is C
32h
42o
9.Various spectral data is consistent with known compound gray wool Cipadessa baecifera Miq A, determines that it is gray wool Cipadessa baecifera Miq A.Gray wool Cipadessa baecifera Miq A's
1h NMR,
13c NMR, HMBC and NOESY data are in Table-1.
Table 1 gray wool Cipadessa baecifera Miq A identification spectral data
Embodiment 2 mouse forced swimming test model
Laboratory animal adopts male mice in kunming, and mice freely ingests drinking-water, body weight about 30 grams during experiment.
Quantitative gray wool Cipadessa baecifera Miq A is placed in mortar, adds 0.5% quantitative carboxymethylcellulose sodium solution grinding and make into suspension, make gray wool Cipadessa baecifera Miq A-0.5% sodium carboxymethyl cellulose suspension; Positive control medicine is venlafaxine.Administering mode is gastric infusion.
Mice is divided into 5 groups at random, be divided into dosage group (15mg/kg) in negative control group (solvent group), gray wool Cipadessa baecifera Miq A low dose group (5mg/kg), gray wool Cipadessa baecifera Miq A, gray wool Cipadessa baecifera Miq A high dose group (50 mg/kg), venlafaxine positive controls (10 mg/kg), only often organize 9-10.
As shown in Figure 1, mice starts administration after the adaptability raising of 5 days, and first time administration counted administration first day, successive administration 7 days the same day, and after last administration, half an hour carries out Behavior test.
Behavioristics's detection method: swimming device is made (high 24 ㎝ of glass jar, diameter 15 ㎝, the depth of water 17 ㎝, water temperature 24 ± 2 DEG C) by transparent organic glass and is placed in one by mice, adapts to after 2 minutes, records the mice floating dead time in latter 4 minutes.The floating dead time is defined as the micro-body of curling up of mice, time in floating state.
Experimental result represents with mean+/-standard error, with the process of t inspection statistics.
Forced swim test is classical antidepressants screening model, the floating dead time that effective antidepressants can make mice swim, as shown in the experimental result of Fig. 2, gray wool Cipadessa baecifera Miq A has significant antidepressant effect, compared with Vehicle controls group, 15,50mg/kg 7 days continuous gastric infusions significantly can reduce the mice floating dead time (p<0.01), and two groups of gray wool Cipadessa baecifera Miq A administration groups are all without significant difference compared with positive controls.
Illustrate that gray wool Cipadessa baecifera Miq A significantly can reduce the mice floating dead time, its action effect is suitable with venlafaxine.
Embodiment 3 Tail suspension test
Laboratory animal adopts male mice in kunming, and mice freely ingests drinking-water, body weight about 30 grams during experiment.
Using 0.5% sodium carboxymethyl cellulose as solvent, the fresh gray wool Cipadessa baecifera Miq A-0.5% sodium carboxymethyl cellulose suspension of preparation before experiment; Positive control medicine is venlafaxine.Administering mode is gastric infusion.
Mice is divided into 5 groups at random, be divided into dosage group (15mg/kg) in negative control group (solvent group), gray wool Cipadessa baecifera Miq A low dose group (5mg/kg), gray wool Cipadessa baecifera Miq A, gray wool Cipadessa baecifera Miq A high dose group (50 mg/kg), venlafaxine positive controls (10mg/kg), only often organize 8-10.As shown in Figure 1, mice starts administration after the adaptability raising of 5 days, and first time administration counted administration first day, successive administration 7 days the same day, and after last gastric infusion, half an hour carries out Behavior test.
Experimental result represents with mean+/-standard error, with the process of t inspection statistics.
According to European Journal of Pharmacology, 2001, the experimental technique recorded in 415:197 builds Tail suspension test model, mice was hung upside down cross bar upper 6 minute apart from ground 60cm, the fixing site of mice is apart from tail slightly 1cm place, adapts to after 2 minutes, observes latter 4 minutes mice dead times, motionless state is defined as mice and stops struggling, and body is relaxation state.
Experimental result represents with mean+/-standard error, with the process of t inspection statistics.
Tail suspension test is classical screening antidepressants experimental model, presents desperate state after mouse tail suspension a period of time, stops struggling.Effective antidepressant drug can make the dead time in mouse tail suspension process shorten.This experiment shows, gray wool Cipadessa baecifera Miq A has significant antidepressant effect, as shown in the experimental result of Fig. 3, compared with Vehicle controls group, 15,50mg/kg gray wool Cipadessa baecifera Miq A administration all significantly can reduce the mouse tail suspension dead time (15 mg/kg p<0.05; 50 mg/kg P<0.01); Compared with positive controls, 15 and 50 mg/kg gray wool Cipadessa baecifera Miq A administration group differences all do not have significance.
Illustrate that gray wool Cipadessa baecifera Miq A can significantly reduce the mouse tail suspension dead time, when dosage reaches 15 mg/kg, its action effect is suitable with venlafaxine.
The spacious field experiment of embodiment 4 mice
Laboratory animal adopts male mice in kunming, and mice freely ingests drinking-water, body weight about 30 grams during experiment.
Using 0.5% sodium carboxymethyl cellulose as solvent, the fresh gray wool Cipadessa baecifera Miq A-0.5% sodium carboxymethyl cellulose suspension of preparation before experiment; Positive control medicine is venlafaxine.Administering mode is gastric infusion.
Mice is divided into 5 groups at random, be divided into dosage group (15mg/kg) in negative control group (solvent group), gray wool Cipadessa baecifera Miq A low dose group (5mg/kg), gray wool Cipadessa baecifera Miq A, gray wool Cipadessa baecifera Miq A high dose group (50 mg/kg), venlafaxine positive controls (10 mg/kg), only often organize 9-10.As shown in Figure 1, mice starts administration after the adaptability raising of 5 days, and first time administration counted administration first day, successive administration 7 days the same day, and after last gastric infusion, half an hour carries out Behavior test.
Mice is put in spacious field, observes 10 minutes, record mice in latter 6 minutes and stop the cumulative time in spacious center court region.Experimental result represents with mean+/-standard error, with the process of t inspection statistics.
Mice spacious field experiment is the experimental model of classical evaluation anxiolytic effect, and mice is placed in a period of time behind spacious field, and it exposes selection preference at exploration middle section and space and embodies its anxiety behavior.Effective anxiolytic drugs can make mice middle section time of staying in the test of spacious field increase.This experiment shows, gray wool Cipadessa baecifera Miq A has significant anxiolytic effect, as shown in the experimental result of Fig. 4, compared with Vehicle controls group, 15,50 mg/kg gray wool Cipadessa baecifera Miq A administrations significantly can increase mice at (15 mg/kg p<0.05 of the spacious center court region time of staying; 50 mg/kg P<0.01); Compared with positive controls, 15 and 50 mg/kg gray wool Cipadessa baecifera Miq A administration group differences do not have significance.
Illustrate that gray wool Cipadessa baecifera Miq A significantly can increase the middle section time of staying in the testing experiment of mice spacious field, when dosage reaches 15mg/kg, action effect is suitable with venlafaxine.
Embodiment 5 spontaneous activity in mice
Laboratory animal adopts male mice in kunming, and mice freely ingests drinking-water, body weight about 30 grams during experiment.
Using 0.5% sodium carboxymethyl cellulose as solvent, the fresh gray wool Cipadessa baecifera Miq A-0.5% sodium carboxymethyl cellulose suspension of preparation before experiment; Positive control medicine is venlafaxine.Administering mode is gastric infusion.
Mice is divided into 5 groups at random, be divided into dosage group (15mg/kg) in negative control group (solvent group), gray wool Cipadessa baecifera Miq A low dose group (5mg/kg), gray wool Cipadessa baecifera Miq A, gray wool Cipadessa baecifera Miq A high dose group (50 mg/kg), venlafaxine positive controls (10 mg/kg), only often organize 9-10.As shown in Figure 1, mice starts administration after the adaptability raising of 5 days, and first time administration counted administration first day, successive administration 7 days the same day, and after last gastric infusion, half an hour carries out Behavior test.
Experimental result represents with mean+/-standard error, with the process of t inspection statistics.
Mice is put in spontaneous activity case, observe 10 minutes, record spontaneous activity in mice situation in latter 6 minutes, experimental result represents with mean+/-standard error, with the process of t inspection statistics.
As shown in the experimental results in Figure 5, compared with matched group, gray wool Cipadessa baecifera Miq A administration group spontaneous activity in mice does not have significant change.Illustrate that the spontaneous activity of gray wool Cipadessa baecifera Miq A to mice has no significant effect, in test dose, remarkable effect be there is no to the neural activity of mice, not there is neurotoxicity.
Claims (2)
1. gray wool Cipadessa baecifera Miq A(cipadesin A) preparing the purposes in anti-depression drug or food, the structure of described gray wool Cipadessa baecifera Miq A as shown in structural formula (1),
Structural formula (1).
2. gray wool Cipadessa baecifera Miq category-A is preparing the purposes in anti-depression drug or food like thing, described gray wool Cipadessa baecifera Miq category-A like the structure of thing as shown in structural formula (2),
Structural formula (2),
Wherein R
1or R
2be selected from hydrogen, carbonyl, C
1~ C
18substituted or non-substituted alkyl, C
1~ C
18substituted or non-substituted aryl.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410826548.1A CN104586837B (en) | 2014-12-26 | 2014-12-26 | Purposes of the gray wool Cipadessa baecifera Miq A and the like in anti-depression drug is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410826548.1A CN104586837B (en) | 2014-12-26 | 2014-12-26 | Purposes of the gray wool Cipadessa baecifera Miq A and the like in anti-depression drug is prepared |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104586837A true CN104586837A (en) | 2015-05-06 |
| CN104586837B CN104586837B (en) | 2017-09-29 |
Family
ID=53113114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410826548.1A Active CN104586837B (en) | 2014-12-26 | 2014-12-26 | Purposes of the gray wool Cipadessa baecifera Miq A and the like in anti-depression drug is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104586837B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853195A (en) * | 2018-07-13 | 2018-11-23 | 北京农学院 | A kind of pharmaceutical composition for treating pig epidemic diarrhea |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101330921A (en) * | 2005-09-12 | 2008-12-24 | 科学与工业研究会 | An extract from xylocarpus useful for the treatment of diabetes and dyslipidemia |
| CN103479650A (en) * | 2013-10-14 | 2014-01-01 | 南京正亮医药科技有限公司 | Application of Phyllanthoid A to in preparation of antidepressant |
-
2014
- 2014-12-26 CN CN201410826548.1A patent/CN104586837B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101330921A (en) * | 2005-09-12 | 2008-12-24 | 科学与工业研究会 | An extract from xylocarpus useful for the treatment of diabetes and dyslipidemia |
| CN103479650A (en) * | 2013-10-14 | 2014-01-01 | 南京正亮医药科技有限公司 | Application of Phyllanthoid A to in preparation of antidepressant |
Non-Patent Citations (2)
| Title |
|---|
| 尹希，等: "木果楝素H抗抑郁活性的实验研究", 《中国科技论文在线》 * |
| 王小英: "大叶山楝和灰毛浆果楝的化学成分及生物活性研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853195A (en) * | 2018-07-13 | 2018-11-23 | 北京农学院 | A kind of pharmaceutical composition for treating pig epidemic diarrhea |
| CN108853195B (en) * | 2018-07-13 | 2021-06-04 | 北京农学院 | Pharmaceutical composition for treating porcine epidemic diarrhea |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104586837B (en) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432184A (en) | Application of great burdock fruit extract in drug production or foods | |
| CN102068535A (en) | Immature bitter orange or bitter orange total flavonoids extract prepared by ethanol reflux and extraction and application thereof | |
| CN101926865B (en) | Spina date seed depression-resolving and nerve-soothing composition and preparation method thereof | |
| CN105338993A (en) | Composition for preventing, relieving or treating colitis, containing complex extracts | |
| CN103169788A (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| CN102641324B (en) | Herba gueldenstaedtia extract and uses thereof | |
| CN102861255B (en) | A kind ofly treat the medicine of influenza and the preparation method of preparation thereof and method of quality control | |
| CN103191198A (en) | Rhizoma corydalis extract as well as preparation method and use thereof | |
| CN105106816A (en) | Traditional Chinese medicine healthcare preparation with protection effect on chemical liver injury and preparing method thereof | |
| CN104586837A (en) | Application of cipadessa cinerascens A and analogues thereof in preparation for anti-depression medicines or foods | |
| CN103156923A (en) | Application of humulus lupulus effective parts applied to preparation of medicine for preventing and improving depression and clinical symptoms | |
| CN102898322B (en) | Compound and preparation method and application thereof | |
| CN102178721A (en) | Application of fiveleaf gynostemma herb suspension and extract to preparation of drug for treating and resisting depression | |
| CN102370884A (en) | Chinese medicinal composition for treating epigastric pain and preparation method thereof | |
| CN102125573A (en) | Use of ginsenoside Rg1 in preparation of antidepressant | |
| CN103880913B (en) | A kind of compound and application thereof with hepatoprotective effect | |
| CN104288142B (en) | The xylocarpus granatum element H and the like purposes in preparing anti-depression drug or food | |
| CN103830374A (en) | Application of three-leaf glycolipid-removal medicine in hyperuricemia | |
| CN103610048A (en) | Health-care food with assistant protecting function to chemical liver injury and preparation method thereof | |
| CN103110890B (en) | Effective part of Xierigasiwei (Mongolian medicine) as well as preparation method, quality detection method and application thereof | |
| CN104546829A (en) | Application of xyloccensin K and analogues thereof in preparation of antidepressant medicines or foods | |
| CN103191238A (en) | Fructus aurantii immaturus or fructus aurantii total-flavonoid extract obtained through ethanol reflux extraction and application thereof | |
| CN101301357A (en) | Use of schisandra chinensis extract in anti-depression medicament | |
| CN103804392A (en) | Two terphenylzidioxazine derivatives and applications thereof | |
| CN104189346A (en) | New pharmaceutical composition capable of promoting gastrointestinal motility and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |